Accéder au contenu
Merck

Cathepsin L, target in cancer treatment?

Life sciences (2009-12-05)
Jacqueline M Lankelma, Daniëlle M Voorend, Temo Barwari, Joris Koetsveld, Anne H Van der Spek, Alexander P N A De Porto, Geeske Van Rooijen, Cornelis J F Van Noorden
RÉSUMÉ

Cathepsin L, a cysteine protease, is considered to be a potential therapeutic target in cancer treatment. Proteases are involved in the development and progression of cancer. Inhibition of activity of specific proteases may slow down cancer progression. In this review, we evaluate recent studies on the inhibition of cathepsin L in cancer. The effects of cathepsin L inhibition as a monotherapy on apoptosis and angiogenesis in cancer are ambiguous. Cathepsin L inhibition seems to reduce invasion and metastasis, but there is concern that selective cathepsin L inhibition induces compensatory activity by other cathepsins. The combination of cathepsin L inhibition with conventional chemotherapy seems to be more promising and has yielded more consistent results. Future research should be focused on the mechanisms and effects of this combination therapy.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Cathepsin L Active human, recombinant, expressed in FreeStyle 293-F cells, ≥90% (SDS-PAGE)